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Abstract
Photoacoustic (PA) tomography enables multiscale, multicontrast and high-resolution imaging of
biological structures. In particular, contrast-enhanced PA imaging offers high-sensitivity noninvasive imaging of neovessel sprout formation and nascent tubules, which are important biomarkers
of malignant tumors and progressive atherosclerotic disease. While gold nanoparticles or nanorods have been used as PA contrast agents, we utilized high-density copper oleate small molecules
encapsulated within a phospholipid surfactant (CuNPs) to generate a soft nanoparticle with PA
contrast comparable to that from gold. Within the NIR window, the copper nanoparticles provided a 4-fold higher signal than that of blood. ανβ3-integrin targeting of CuNPs in a MatrigelTM
angiogenesis mouse model demonstrated prominent (p<0.05) PA contrast enhancement of the
neovasculature compared with mice given nontargeted or competitively inhibited CuNPs. Furthermore, incorporation of a Sn 2 lipase-labile fumagillin prodrug into the CuNP outer lipid
membrane produced marked antiangiogenesis in the same model when targeted to the
ανβ3-integrin, providing proof of concept in vivo for the first targeted PA – drug delivery agent.
Key words: copper, nanoparticle, near-infrared imaging, photoacoustic imaging, angiogenesis
imaging, anti-angiogenic therapy.

Introduction
As an important component of an expanding
vascular network the neovasculature can be viewed as
a biomarker of inflammation associated with tumor
aggressiveness or atherosclerotic plaque progression.
[1-3] To date, noninvasive imaging of angiogenesis
has been essentially a preclinical endeavor, although
imaging candidates have reached the clinical testing
level for MRI and nuclear medicine. Nuclear medicine

probes, although exquisitely specific for neovascular
biosignatures, such as the ανβ3-integrin, are not specific to angiogenesis, since this adhesion molecule is
activated on numerous cell types present in tumors or
atherosclerotic lesions. [4-6] By comparison, MRI
paramagnetic nanoparticle agents are often vascular-constrained by size and very specific for neoendothelial expression of ανβ3-integrin, but such agents
http://www.thno.org
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have experienced other roadblocks in the clinic. [7]
Photoacoustic molecular imaging offers noninvasive
vascular-constrained detection of angiogenic biomarkers with very high resolution imaging of the
neovasculature.
Different imaging modalities have different
characteristic resolution limits, with microscopic images having the highest resolution for thin specimens.
For biomedical instrumentation, ultra-high spatial
resolution MRI at 3.0T and high resolution CT provide in vivo blood vessel images but with a poorer
resolution, in the range of 200 to 500 μm, which is
inadequate for discrete neovessel imaging. [8-12]
Photoacoustic (PA) imaging combines the advantages
of ultrasound imaging and optical imaging and offers
high depth-to-resolution ratios at different spatial
scales, ranging from organelles to organs, [13] as well
as unique and important physiological assessments,
such as differential circulating blood oxygenation
levels.
Previous studies have confirmed that PA imaging’s utility can be markedly extended with exogenous contrast agents. [14-16] In many instances, these
contrast agents have been based on gold cubes,
spheres, or rods with particle sizes greater than the
renal clearance threshold (<8 to 10 nm), creating difficult translational challenges when proving
long-term safety in man. Gold nanobeacons (120-160
nm) were developed to achieve the large absorption
cross-sections of bigger solid gold particles by suspending a multitude of small gold nanoparticles (3-5
nm) in a hydrophobic matrix encapsulated with
phospholipid (160 nm). [17] Moreover, the optical
absorption wavelength of nanoparticles was tunable
well into the NIR optical window, minimizing endogenous absorption and maximizing PA imaging
depth.
However, the pressure of healthcare economics
has placed an emphasis on driving the costs of imaging studies down, and we have thus sought lower cost
biocompatible alternatives to gold. We hypothesized
that nanoparticles entrapping high densities of organically soluble small molecular weight copper
complexes could provide an inexpensive and effective
approach to neovascular targeted PA imaging. The
choice of copper as a cheaper, biocompatible alternative to gold was independently supported by a recent
report describing nontargeted crystalline copper sulfide nanoparticles as PA contrast agents for deep tissue imaging at 1064 nm. [18] In this research, a soft
noncrystalline ανβ3-targeted copper-oleate nanoparticle (ανβ3-CuNP) was developed and its PA imaging
signal with respect to blood and the previously reported gold nanobeacons was characterized [17] as a
function of NIR wavelength and with varying nano-
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particle concentrations. The in vivo efficacy of
ανβ3-CuNPs for high-resolution imaging of mouse
neovasculature was examined in a Matrigel™ model
of angiogenesis. Furthermore, the theranostic antiangiogenic potential of ανβ3-CuNPs incorporating a
novel Sn 2 lipase-labile fumagillin prodrug (Fum-PD)
was also studied. [19]

Materials and Methods
Reagents
Unless otherwise listed, all solvents and reagents
were purchased from Aldrich Chemical Co. (St. Louis,
MO) and used as received. Anhydrous chloroform
and methanol were purchased from Aldrich Chemical
Co. Poly (styrene-b-acrylic acid) (PS-b-PAA) was
purchased from Polymer Source Inc. (Montreal,
Canada). High purity egg yolk phosphatidylcholine
was purchased from Avanti Polar Lipids, Inc. Cholesterol and cooper oleate were purchased and used
as received from Aldrich Chemical Co. (St. Louis,
MO). Sorbitan monolaurate was purchased from Aldrich. Argon and nitrogen (Ultra High Purity: UHP,
99.99%) were used for storage of materials. The Spectra/Por membrane (Cellulose MWCO: 20,000 Da)
used for dialysis was obtained from Spectrum Medical Industries, Inc. (Laguna Hills, CA).

Preparation of Sn 2 lipase labile Fumagillin
prodrug
Synthesis of the Sn 2 prodrug was accomplished
in two steps: 1) saponifying fumagillin dicyclohexylamine salt to fumagillol, and 2) esterifying the
product
with
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine
(PAzPC). [19] Briefly, fumagillin dicyclohexylamine
salt (NCI) in 1:1 methanol:water was treated with 35%
NaOH, stirred in an ice bath for 2 h, warmed to room
temperature, treated with another equivalent of 35%
NaOH, and then stirred in an ice bath until the starting material was not detected by TLC (∼4 h). After
evaporating the methanol and solubilizing in ethyl
acetate, the mixture was extracted with 5% citric acid,
brine, bicarbonate, and brine again, then dried with
MgSO4 and concentrated in vacuo. The crude product
was purified with activated charcoal in acetonitrile
and then filtered through a celite pad. (Yield: a colorless solid, 59 mg (70%). 1H NMR (CD3OD): δ 5.20 (t,
1H), 4.3 (m, 1H), 3.42 (m, 1H), 3.38 (s, 3H), 2.88 (d, 1H),
2.63 (t, 1H), 2.51 (d, 1H), 2.1–2.3 (m, 2H), 2.2 (m, 1H),
1.89 (d, 1H), 1.7–1.9 (m, 2H), 1.8 (d, 3H), 1.7 (d, 3H),
1.17 (s, 3H), 0.96 (m, 1H). HR-MS found: MH+ (283.3).
A solution of C16-09:0 (COOH) PC
1-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine,
followed by 4-dimethylaminopyridine (DMAP) and
http://www.thno.org
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N, N'-dicyclohexyl-carbodiimide (DCC), was added
to fumagillol in dry dichloromethane. The reaction
mixture was stirred overnight at ambient temperature
then passed over a short pad of silica gel using
EtOAc/n-hexane. The filtered solvent was removed in
vacuo, and the oil residue was purified by column
chromatography on SiO2 using EtOAc/n-hexane for
elution to yield the fumagillin prodrug (Fum-PD)
compound as a pale yellowish solid (yield: 54%). 1H
NMR (CDCl3): δ 0.88 (t, 3H), 1.22–1.37 (m, 37H),
1.58–1.96 (m, 20H), 2.26–2.60 (m, 7H), 3.40 (m, 12H),
3.48 (m, 3H), 3.86–4.00 (m, 4H), 4.10–4.37 (m, 5H), 5.21
(m, 1H). HR-MS found: 930.6 (MH+).

Preparation of copper nanoparticles
Copper-oleate (260 mg) dissolved in toluene was
suspended in almond oil (4 ml), gently vortexed to
homogeneity, and filtered through a small bed of
cotton. The solvent was evaporated under reduced
pressure at 45°C, leaving a mixture containing 65 mg
of copper oleate per ml. The surfactant co-mixture
included high-purity egg yolk phosphatidylcholine
(91.9
mol%),
cholesterol
(8
mol%),
and
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ανβ3-peptidomimetic antagonist conjugated to
PEG2000-phosphatidylethanolamine (0.1 mol%; Kereos, St. Louis, MO, USA). Therapeutic ανβ3-CuNPs
incorporated the Sn 2 lipase labile fumagillin prodrug
(2.28 mol%) at the equimolar expense of phosphatidylcholine. The surfactant co-mixtures were dissolved
in chloroform, evaporated under reduced pressure,
dried in a 40°C vacuum oven overnight, and dispersed into water by probe sonication. This suspension was combined with the copper oleate-almond oil
mixture (20% v/v), distilled deionized water (77.3%
w/v), and glycerin (1.7%, w/v) and continuously
processed at 20,000 psi for 4 min with an S110 Microfluidics emulsifier (Microfluidics, Newton, MA, USA)
at 4°C. The copper nanoparticles (CuNPs) were dialyzed against water using a 20-kDa MWCO cellulose
membrane for a prolonged period of time and then
passed through a 0.45 µm Acrodisc syringe filter (Pall
Life Sciences, East Hills, NY, USA). To inhibit lipid
oxidation, the CuNPs were stored under an argon
atmosphere, typically at 4°C. (Figure 1)

Figure 1. Synthesis and physiochemical characterization of CuNPs. (a) schematic of the concept of CuNPs with fumagillin prodrug; (b) hydrodynamic particle size distribution
from DLS. The nominal hydrodynamic diameters of αvβ3-CuNPs and fumagillin prodrug CuNPs were typically 190 nm ± 15 nm, (c). Anhydrous state atomic force microscopy
(AFM) image of CuNPs (drop-deposited on glass) Average height: 80 nm ± 12 nm. (d). EDX spectrum generated from the SEM image.

http://www.thno.org
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The nominal hydrodynamic diameter (Dh) of the
αvβ3-CuNPs and the fumagillin prodrug CuNPs was
determined by dynamic light scattering (DLS) measurements (Brookhaven ZetaPlus, Brookhaven Instruments Corporation) in aqueous solution, were
typically 190 nm ± 15 nm (std error), with a polydispersity of 0.09 ± 0.01, and a zeta potential of -23 ± 06
mV. Incorporation of the prodrug at 2.28 mol% (~0.5
mM) within the surfactant co-mixture had negligible
impact on particle sizes.
The ανβ3-integrin antagonist was a quinalone
nonpeptide developed by Lantheus Medical Imaging
(Billerica, MA, USA) and synthesized by Kereos (U.S.
Patent 6,511,648 and related patents). The vitronectin
antagonist was reported and characterized as the
111In-DOTA conjugate RP478 and cyan 5.5 homologue
TA145. [20] The homing specificity of the ligand was
demonstrated and characterized with Matrigel plug
implanted in Rag1tm1Mom Tg (Tie-2-lacZ) 182-Sato and
C57Bl/6 mice. [14]
The reference gold nanobeacons (GNBs) used in
this study were prepared and characterized as previously described. [14] The GNBs were in a 20 vol%
suspension with a nominal particle size of 160 nm,
containing
6120
gold-oleate
particles
(3-5
nm)/nanobeacon, with a gold content of 1080 µg/g.

Matrigel™ plug mouse model of angiogenesis
All animal studies were conducted in accordance
with protocols approved by the Animal Care and Use
Committee of Washington University Medical School.
Athymic nude-mice (Harlan Labs, Indianapolis,
IN) with body weights ranging from 23 to 27 g were
obtained. Anesthesia was induceod by ketamine (100
mg/ml) and xylazine (20 mg/ml), which were maintained with 0.5% to 1% isoflurane in oxygen, with
ventilator support and supplemental temperature
support. Matrigel (0.5 ml, BI, Biosciences, San Jose,
CA, USA) enriched with fibroblast growth factor-2
(500 nm/ml; Sigma-Aldrich, St. Louis, MO, USA) and
heparin was implanted subcutaneously along the
mouse flank. The nude mice (n = 12) were randomly
distributed into four groups to test (1) the efficacy of
ανβ3-CuNPs for PA molecular imaging of angiogenesis in vivo and (2) the efficacy of ανβ3-CuNPs with
Fum-PD as a theranostic agent. For the first test, three
groups were compared on day 18 using PA imaging:
(1) ανβ3-CuNPs without Fum-PD (integrin targeted,
n=3); (2) nontargeted CuNPs (nonspecific entrapment,
n=3) and (3) ανβ3-almond oil nanoparticle (NP) followed after 10 min by ανβ3-CuNPs without Fum-PD
(specific competition, n=3). To address the second
question within the same experimental design, (4)
ανβ3-CuNPs with Fum-PD were administered on days
11 and 15, following Matrigel implantation, and the

127
effect on angiogenesis was assessed on day 18 with
ανβ3-CuNPs without Fum-PD (n=3). All treatments
were injected via tail vein at 2 μl/g body weight of the
20 vol% nanoparticle suspensions. For each animal
dynamic PA imaging was performed before injection
(baseline, 0 min) and then repeated every 30 min over
270 minutes post-injection.

Photoacoustic imaging
A reflection-mode PA imaging system using
dark-field ring-shaped illumination [21] was pumped
by a Q-switched Nd:YAG (LS-2137; Lotis TII) laser
with <15-ns pulse duration and a 10-Hz pulse repetition rate. The light energy on the sample surface was
controlled to conform to the American National
Standards Institute (ANSI) standard for maximum
permissible exposure. A 10 MHz central frequency,
spherically focused (2.54 cm focus length, 1.91 cm
diameter active area element, and 68% nominal
bandwidth (One way -6 dB bandwidth is ~96%) ultrasonic transducer (V315; Panametrics-NDT, Waltham, MA, USA) acquired the generated PA signals.
The signal was amplified by a low-noise amplifier
(5072PR; Panametrics-NDT), and recorded using a
digital oscilloscope (TDS 5054; Tektronix, Beaverton,
OR, USA) with 50-MHz sampling. PA signal fluctuations due to pulse-to-pulse energy variation were
compensated for by signals from a photodiode
(DET110; Thorlabs, Newton, NJ, USA), which sampled the energy of each laser pulse.
Prior to in vivo imaging, two preliminary experiments were performed. In preliminary experiment 1, individual samples of CuNPs (20 vol%) and
bovine blood (hct. ~45%) were placed into individual
transparent plastic tubes (ID, 510 µm) and imaged by
the PA system at 767 nm. The A-line signals from
these two tubes are presented in Figure 2 as superimposed waveforms.
In preliminary experiment 2, the transparent
Tygon tubes (ID, 510 µm) were filled with CuNPs (20
vol %), GNBs (20 vol%), and whole bovine blood (hct.
~45%). They were imaged at varying wavelengths
between 730 nm and 830 nm. As an extension of this
experiment, CuNPs were serially diluted from 6.0 µM
to 0.17 µM and imaged at 750 nm, 760 nm, 770 nm, 780
nm, and 790 nm. In each experiment, the maximum
amplitudes of the A-line signals (n=5) at each wavelength were averaged.
Finally, in vivo imaging of angiogenesis in the
Matrigel Plug model was performed. A linear translation stage (XY-6060; Danaher Motion, Rad ford, VA,
USA) was used for raster scanning to obtain 3-D PA
data. A computer controlled the stage and synchronized it to the data acquisition. To shorten the data
acquisition time, a continuous scan was used without
http://www.thno.org
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signal averaging. Typical scanning values are as follows: voxel dimensions, 0.1 × 0.2 mm; laser pulse
repetition rate, 10 Hz; acquisition time, ~20 min.
In vivo imaging was performed using ventilated
anesthetized mice with shaved flanks, constantly
warmed to 37°C by a heating block and positioned
immediately beneath the transparent clear membrane.
PA imaging was performed at 767 nm, as previously
used for GNB in vivo. [14] Similarly, the vessel-integrated PA amplitude, calculated by integrating the enveloped PA signal amplitude over the blood
vessel region, was used to quantify the degree of angiogenesis. The vessel-integrated PA amplitude was
normalized to that of the pretreatment level during
the analysis.

Statistical Analysis
Data were analyzed using analysis of variance
(GraphPad Prism Ver. 6.03) (p < 0.05). Data are presented as the mean ± standard error of the mean unless otherwise stated.
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were serially titrated from 6.0 µM to 0.17 µM and
studied at NIR wavelengths between 750 nm and 790
nm (Figure 4 (A)). PA amplitude decreased with reductions in CuNP concentration level, but the magnitude of signal diminishment was generally less than
the percent change in CuNP level. This was particularly notable for the higher concentrations, between
6.0 µM and 1.5 µM. The magnitude of the CuNP’s PA
signal was greatest at 750 nm and 760 nm. At higher
wavelengths, the magnitude of the CuNP signal
trended lower, with the greatest contrast loss seen at
the lower CuNP concentrations. It can be calculated
from the extinction coefficient spectrum shown in
Figure 4 (B) that the extinction coefficient of CuNPs at
700 nm was 1.3 times as strong as that at around 770
nm. However, the laser energy at 767 nm (the peak of
laser energy) is an order of magnitude stronger than
that at 700 nm. Therefore, neovascular imaging signal
peaks around 767 nm.

Results
Given the inherently strong PA signal of hemoglobin, the efficacy of PA contrast agents for targeted
molecular imaging of neovascular integrin expression
is dependent on the strength and differentiation of its
signal from the blood background. The PA signal of
CuNPs (20 vol%) was compared with whole bovine
blood (45% hct.) at 767 nm. As seen in Figure 2, the
time-aligned PA signal of the copper NP emulsion
was markedly greater than that of the bovine blood at
767. The peak-to-peak signal of the CuNPs (2.3 a.u.)
was 4-fold greater than that of blood (0.58 a.u.) at 767
nm, suggesting that the PA signal of neovascular
bound CuNPs could be readily detectable in vivo.
GNBs have been previously shown to produce
strong PA contrast in vivo when applied to sentinel
lymph node imaging or when targeted to neovasculature in vivo. [14, 17, 22, 23] The PA signal enhancement of CuNPs relative to blood (45% hct.) was compared to the signal of GNBs relative to blood across a
NIR frequency range of 730 nm to 830 nm (Figure 3)
on an equal nanoparticle number basis. Over almost
the entire spectrum, the CuNPs signal strength relative to blood was around 5-fold greater with a noticeable decline beyond 820 nm. In general, the PA
ratios of GNBs and CuNPs were very similar except
between 760 nm and 790 nm, with the greatest divergence between GNBs and CuNPs at 770 nm, at which
point the gold contrast result was nearly twice that of
copper. GNB particles experienced the same declining
results as CuNPs from 800 nm and beyond.
The concentration dependence of CuNPs’ signals as a function of frequency was examined. CuNPs

Figure 2. Overlay of PA signals from CuNPs (20 vol%) and blood (whole bovine
blood, hct. 45%;). CuNPs and blood samples were placed into transparent TygonTM
tubes (ID = 510 µm) and imaged by the PA system at 767 nm. The peak-to-peak PA
signal from the CuNPs was 4 times greater than that of the blood at 767 nm.

Figure 3. Equal-nanoparticle-based ratio of peak-to-peak PA signal amplitudes from
previously reported gold nanobeacons (20 vol%) [14] and CuNPs (20 vol%) to those
of whole bovine blood (hct. 45%) over the 730 – 830 nm range. Over the whole
spectrum, PA signals of CuNPs were markedly greater than those of the blood. In
general, the PA ratios of GNBs and CuNPs relative to blood were similar.

http://www.thno.org
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Figure 4. (A) PA signals from copper nanoparticles (20 vol%) in a transparent Tygon tube filled with serially diluted copper nanoparticles (0.17 µM, 0.38 µM, 0.75 µM, 1.5 µM,
3.0 µM, 6.0 µM) at laser wavelengths from 750 nm to 790 nm, with 10 nm step size. A nonlinear relationship between the PA amplitude and CuNP concentration was observed.
(B) Normalized extinction coefficient spectrum of the CuNPs (20 vol%) at laser wavelengths from 600 nm to 800 nm.

Figure 5. In vivo PA images of the Matrigel plug area implanted in 4 groups of mice 18 days prior to imaging. (A)-(B) Targeted CuNPs group: mice received αvβ3-CuNPs just before
PA imaging. The enhanced neovasculature is marked by arrows in B. (C)-(D):Nontargeted CuNPs group: mice received nontargeted CuNPs right before PA imaging
(E)-(F):Competition group: mice received a competitive dose of αvβ3-oil only NP (1:1) 10 minutes prior to imaging, followed by αvβ3-CuNPs right before imaging. (G)-(H) Fum-PD
group: mice received αvβ3-CuNPs with Fum-PD 11 and 15 days after the Matrigel implantation, and αvβ3-CuNPs w/o Fum-PD right before PA imaging. Comparing the PA images
of the nontargeted, competition, and Fum-PD groups at 0 min and 170 min, very little change in PA signals can be found. For all PA images, laser wavelength = 767 nm.

To provide robust assessment of PA signal enhancement due to the CuNPs, in vivo neovascular
imaging was studied in the Matrigel plug model in
mice. Mice implanted with Matrigel™ 18 days previously received either ανβ3-CuNPs, nontargeted
CuNPs, or ανβ3-CuNP preceded by 10 minutes with a
competitive dose ανβ3-oil only NPs (1:1). As seen in
Figure 5, at 0 min, forming neovessels were observed
by the inherent PA contrast imparted by erythrocyte
hemoglobin. The magnitude of the signal varied
among animals with the extent of neovascular proliferation. Following ανβ3-CuNP injection, the magnitude of the PA signal in these immature tubules
clearly increased, and numerous incomplete vascular
sprouts appeared, as we have previously reported for
GNBs. [14] The formation of the neovessel shoots depicted an early evolution stage of a dense and irregular microvasculature. In contradistinction to the ani-

mals receiving ανβ3-CuNPs, those given nontargeted-CuNPs had very little increase in the vessel-integrated PA amplitude. As shown, a minimal
passive accumulation of the CuNPs in the forming
bridges and sprouts combined with a modest amount
of blood pool enhancement relative to the neovessel
tubules at 0 min. We have previously reported that
blood pool enhancement for GNBs in the intact microvasculature surrounding the Matrigel implant was
negligible, [14] but within the plug, the slow moving
blood may be associated with very slow washout. In
the competition group at 170 min, very little change in
the PA signal from the forming vascular tubules or
sprouts was observed. In this group, the pretreatment
binding of the ανβ3-oil NPs appeared to have blocked
most of the receptors for the ανβ3-CuNP and even
precluded significant passive accumulation. Figure 6
presents the average change in the vessel-integrated
http://www.thno.org
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PA amplitude between the three treatment groups,
showing that the ανβ3-CuNPs increased PA contrast,
while the nontargeted-CuNP did not (p<0.05). Moreover, the specificity of targeting the neovasculature
was again demonstrated by the low vessel-integrated
PA amplitude measured in the competition group
versus the ανβ3-CuNP group (p<0.05), and even relative to the nontargeted control. Dynamic accumulation of PA contrast measured in the ανβ3-CuNP group
increased progressively over the 230 minutes post
injection interval (Figure 7).

130
plitude in these animals was determined on day 18. At
baseline, the amount of neovasculature observed by
PA imaging was sparse, but no more so than that in
the other groups. Moreover, following ανβ3-CuNP
injection there was little sprouting enhancement at
170 minutes. As shown collectively in Figures 5 and 6,
the vessel-integrated PA amplitude change was similar to that measured in the nontargeted-CuNP group,
and appeared related to modest particle accumulation
in the nascent tubules, with less signal related to
sprout formation. Although drug delivery and imaging were not performed simultaneously to minimize
the differential animal handling between the groups,
these results illustrated the potential of CuNPs as vehicles for drug delivery and diagnosis.

Discussion

Figure 6. Vessel-integrated PA amplitude (normalized to the baseline, i.e., the
vessel-integrated PA amplitude at 0 min) at 170 min post-injection for four groups of
mice. The vessel-integrated PA amplitude for the αvβ3-targeted group increased more
than that of the other three groups (*P<0.05). Almost no increase in vessel-integrated
PA amplitude was measured in the competition group, and a slight increase was
observed in the non-targeted and Fum-PD groups.

Figure 7. Vessel-integrated PA amplitude vs. post-injection time for the αvβ3-CuNPs
group. The vessel-integrated PA amplitude increased progressively over the 230 min
post injection interval.

In a second aspect of the Matrigel™ angiogenesis
experiment, fumagillin-prodrug (Fum-PD), [24, 25],
was incorporated into the phospholipid surfactant at
2.28 mol%. The chemical synthesis, characterization,
and in vivo effectiveness of Fum-PD incorporated into
perfluorocarbon nanoparticles has been previously
reported. [19, 26] ανβ3-CuNP (2 µl/g) incorporating
Fum-PD was administered on days 11 and 15 post
Matrigel™ implant, and the vessel-integrated PA am-

Photoacoustic imaging has demonstrated broad
applications in the imaging and physiological characterization of the vasculature, particularly the microvasculature [13, 27], and microvascular expansion
driven by brain tumor hypoxia [28]. The vascular
endothelium provides numerous “road-signs” reflecting its developmental stage, as seen for the neovasculature, or its state of activation, as seen with inflammation. In each instance, specific PA characterization depends on molecular imaging through the
recognition of unique endothelial biomarkers. [15, 16,
22, 29-33] In the present study, sparse activated
ανβ3-integrin was selected as a biomarker of angiogenesis. While we have previously reported dynamic
imaging of the forming neovasculature with gold
nanobeacons, the high and unpredictable cost of gold,
and the unclear long-term safety of larger nonmetabolizable nanoparticles, such as carbon fullerenes or
nanotubes, led to the design and development of
CuNPs. While free copper can elicit systemic toxicity,
CuNPs are comprised of high densities of small organometallic complexes that can be eliminated
through the bile or urine, minimizing the risk potential for this agent. [34] In the present study, CuNPs
offered comparable PA contrast enhancement, on an
equal particle basis, to GNBs both in vitro and in vivo.
In vivo PA imaging was performed at 767 nm,
which was optimal for the previously targeted GNB
agent, but the spectral assessments of CuNP relative
to blood and as a function of particle concentration
suggest 740 or 750 nm may be preferred for targeting
sparse epitopes like adhesion molecules. Also, the
time for maximum neovascular signal was found to
be nearly 4 hours in the Matrigel model, but similar
particles administered in vivo for deeper-tissue angiogenesis imaging with MRI were shown to provide
minimal targeting benefit after 2 hours. [35, 36] The
difference likely relates to vascular vasoconstriction
http://www.thno.org
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with reduced blood flow to the skin in the subcutaneous Matrigel implant model, which is aggravated
by the cooling effects of acoustically coupling the PA
probe to the body during anesthesia, despite provision of supplemental heating to maintain core body
temperatures. Lastly, CuNPs were designed to be
vascular constrained agents to reduce nonspecific
signal generated by interactions with extravascular
cells expressing the ανβ3-integrin. Close examination
of the 170-minute PA images in Figure 5 showed negligible extravasation of the particles. Although much
attention has been attributed to the leakiness of angiogenesis, even in the sprouting regions where the
neovasculature is essentially open-ended, no evidence
of nanoparticle accumulation beyond the tips of the
forming neovessel branches was noted. Moreover,
this was a consistent observation, regardless of
whether the nanoparticles were integrin-targeted or
not.
Fumagillin prodrug was incorporated into the
phospholipid surfactant of CuNPs and demonstrated
to elicit anti-angiogenic effects in this Matrigel model.
Microanatomically, the treatment virtually eliminated
the rich web of sprouts in the mice receiving
ανβ3-CuNPs without Fum-PD. “Pruning” of neovasculature was first suggested by Jain in a visionary
manner, but in this study, the concept was visually
apparent. [37-39] Despite all of the extensive clinical
research on the effects and benefits of anti-angiogenesis therapy in cancer and selected other
pathologies, virtually all of the work has centered on
vascular endothelial growth factor (VEGF) inhibition.
While VEGF is a clear driver of angiogenesis, it elicits
pleotropic effects and is not solely responsible for
neovascularization. [40] Moreover, VEGF is produced
by a variety of cell types, making effective blockade of
the growth factor challenging. Typically, relatively
high dosages of medicants are used clinically and
these treatments have well known side-effects. [41]
As reported by others, fumagillin is an antiangiogenic agent which is specific for proliferating endothelial cells, but its clinical analogue, TNP-470,
possessed only antidotal effectiveness in the clinic at
the high doses required, which were accompanied by
numerous toxicities, including neurocognitive dysfunction. [42-44] Fumagillin can be effectively incorporated into the phospholipid surfactant of nanoparticles for targeted delivery of anti-angiogenesis therapy through a mechanism referred to as “contact facilitated drug delivery” (CFDD) at a small fraction of
the dosages previously used systemically. [2, 45, 46]
Tethering of the lipid-encapsulated nanoparticle to
the target cell surface facilitates the interaction and
hemifusion of the two lipid membranes, which affords the passive transfer of the drug and phospho-
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lipids from the nanoparticle surface to the outer leaflet
of the target cell membrane. The drug is then translocated to the inner leaflet through an ATP-dependent
mechanism. [47, 48] CFDD eliminates the need for
particle internalization with subsequent endosomal
drug payload escape.
However, pharmacokinetic studies showed that
fumagillin dissolved into the lipid membrane was
substantially lost prematurely during circulation to
the target neovasculature, despite its effectiveness in
vivo. Fum-PD was developed to address this early
release by coupling the drug through the Sn 2 acyl
position (i.e., the stereospecific hydroxyl group of the
second carbon of glycerol). Subsequent transfer of the
monolayer components into the target cell membrane
allows cytosolic phospholipases to enzymatically
cleave the Sn 2 ester and release the drug, allowing it
to diffuse into the cytosol for effect. Fum-PD as well as
other similar prodrug compounds is incorporated
stably into the hydrophobic aspects of the particle
membrane. Importantly, Sn 2 lipase-labile prodrugs
within the particle lipid membrane are stable in blood
and plasma, even in the presence of excess exogenous
lipase, and do not passively exchange to
co-circulating RBC. [49] The results of the present
research show the first example of a systemically targeted antiangiogenic drug delivery with a photoacoustic contrast nanoparticle. Given the rapid developments in hardware and software for PA imaging,
one can envision numerous medical applications for
low-cost CuNPs particles to target neovascular or
alternative endothelial biosignatures for diagnostic
and theranostic purposes.
Unlike current VEGF inhibitors, fumagillin-prodrug specifically targeted to angiogenic
vessels suppresses angiogenesis, clinical disease, and
inflammation in a preclinical model of rheumatoid
arthritis (RA). [50] Enhanced endothelial nitric oxide
(NO) modulates local macrophage inflammatory activity through NO activation of AMP-activated protein kinase (AMPK). In vivo, NO-induced AMPK activation increased autophagy by inhibiting mammalian target of rapamycin (mTOR) activity. Increased
autophagy mediated the degradation of IkappaB kinase (IKK) and suppressed NF-κB. The suppression of
NF-κB was associated with diminished inflammatory
cytokine release. Importantly, the NO mediated inhibition of inflammation was reversed in vitro and in
vivo by the co-administration of N(G)-nitro-L-arginine
methyl ester (L-NAME), a nitric oxide synthase inhibitor. These unique anti-angiogenic and anti-inflammatory properties of Fum-PD nanotherapy
may be applicable to the treatment of other angiogenesis-dependent diseases.
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Conclusion
Soft copper oleate nanoparticles were synthesized and conceptually shown to offer effective photoacoustic contrast comparable to gold-based agents,
but at a much lower cost and higher material availability. CuNPs possessed strong PA contrast relative to
blood from 730 nm to 830 nm, which was similar to
the PA signal response of gold nanobeacons relative
to blood overall. In the Matrigel angiogenesis model,
ανβ3-CuNPs markedly enhanced neovessel tubules
and identified a myriad of incomplete emergent neovascular sprouts, which were not well detected or
specifically differentiated as angiogenesis with inherent PA imaging. ανβ3-CuNPs effectively delivered
fumagillin-prodrug, a potent anti-angiogenic therapy,
in vivo, providing the first example of a systemically
targeted drug delivery therapy with a photoacoustic
contrast agent.
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